Literature DB >> 15014592

The Comorbidity of Major Depression and Anxiety Disorders: Recognition and Management in Primary Care.

Robert M. A. Hirschfeld1.   

Abstract

BACKGROUND: Depressive and anxiety disorders commonly occur together in patients presenting in the primary care setting. Although recognition of individual depressive and anxiety disorders has increased substantially in the past decade, recognition of comorbidity still lags. The current report reviews the epidemiology, clinical implications, and management of comorbidity in the primary care setting.
METHOD: Literature was reviewed by 2 methods: (1) a MEDLINE search (1980-2001) using the key words depression, depressivedisorders, and anxietydisorders; comorbidity was also searched with individual anxiety diagnoses; and (2) direct search of psychiatry, primary care, and internal medicine journals over the past 5 years.
RESULTS: Between 10% and 20% of adults in any given 12-month period will visit their primary care physician during an anxiety or depressive disorder episode (although typically for a nonpsychiatric complaint); more than 50% of these patients suffer from a comorbid second depressive or anxiety disorder. The presence of depressive/anxiety comorbidity substantially increases medical utilization and is associated with greater chronicity, slower recovery, increased rates of recurrence, and greater psychosocial disability. Typically, long-term treatment is indicated, although far less research is available to guide treatment decisions. Selective serotonin reuptake inhibitor antidepressants are the preferred treatment based on efficacy, safety, and tolerability criteria. Knowledge of their differential clinical and pharmacokinetic profiles can assist in optimizing treatment.
CONCLUSION: Increased recognition of the high prevalence and negative psychosocial impact of depression and anxiety disorder comorbidity will lead to more effective treatment. While it is hoped that early and effective intervention will yield long-term benefits, research is needed to confirm this.

Entities:  

Year:  2001        PMID: 15014592      PMCID: PMC181193          DOI: 10.4088/pcc.v03n0609

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  74 in total

1.  Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders.

Authors:  R Hoehn-Saric; P Ninan; D W Black; S Stahl; J H Greist; B Lydiard; S McElroy; J Zajecka; D Chapman; C Clary; W Harrison
Journal:  Arch Gen Psychiatry       Date:  2000-01

2.  Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties.

Authors:  H A Pincus; T L Tanielian; S C Marcus; M Olfson; D A Zarin; J Thompson; J Magno Zito
Journal:  JAMA       Date:  1998-02-18       Impact factor: 56.272

3.  Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study.

Authors:  R Noyes; M J Garvey; B L Cook; L Samuelson
Journal:  J Clin Psychiatry       Date:  1989-05       Impact factor: 4.384

4.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

5.  Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data.

Authors:  W Coryell; J Endicott; N C Andreasen; M B Keller; P J Clayton; R M Hirschfeld; W A Scheftner; G Winokur
Journal:  Am J Psychiatry       Date:  1988-03       Impact factor: 18.112

6.  Depression in patients with coronary artery disease.

Authors:  M B Gonzalez; T B Snyderman; J T Colket; R M Arias; J W Jiang; C M O'Connor; K R Krishnan
Journal:  Depression       Date:  1996

7.  Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.

Authors:  R L Spitzer; K Kroenke; J B Williams
Journal:  JAMA       Date:  1999-11-10       Impact factor: 56.272

8.  Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey.

Authors:  R C Kessler; C B Nelson; K A McGonagle; J Liu; M Swartz; D G Blazer
Journal:  Br J Psychiatry Suppl       Date:  1996-06

Review 9.  Paroxetine: a review.

Authors:  M Bourin; P Chue; Y Guillon
Journal:  CNS Drug Rev       Date:  2001

10.  Comorbid anxiety disorder and the functioning and well-being of chronically ill patients of general medical providers.

Authors:  C D Sherbourne; K B Wells; L S Meredith; C A Jackson; P Camp
Journal:  Arch Gen Psychiatry       Date:  1996-10
View more
  161 in total

1.  The roles of comorbidity and trauma exposure and its timing in shaping HPA axis patterns in depression.

Authors:  Stefanie E Mayer; Melissa Peckins; Kate R Kuhlman; Nirmala Rajaram; Nestor L Lopez-Duran; Elizabeth A Young; James L Abelson
Journal:  Psychoneuroendocrinology       Date:  2020-06-17       Impact factor: 4.905

2.  Improving risk prediction for depression via Elastic Net regression - Results from Korea National Health Insurance Services Data.

Authors:  Min-Hyung Kim; Samprit Banerjee; Sang Min Park; Jyotishman Pathak
Journal:  AMIA Annu Symp Proc       Date:  2017-02-10

Review 3.  Anxiety and diabetes: Innovative approaches to management in primary care.

Authors:  Allison Bickett; Hazel Tapp
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-06

4.  Prevalence of mental and social disorders in adults attending primary care centers in Bosnia and Herzegovina.

Authors:  Teresa Broers; Geoffrey Hodgetts; Olivera Batić-Mujanović; Verica Petrović; Melida Hasanagić; Marshall Godwin
Journal:  Croat Med J       Date:  2006-06       Impact factor: 1.351

5.  Transdiagnostic neural correlates of volitional emotion regulation in anxiety and depression.

Authors:  Jacklynn M Fitzgerald; Heide Klumpp; Scott Langenecker; K Luan Phan
Journal:  Depress Anxiety       Date:  2018-11-08       Impact factor: 6.505

6.  Depression and anxiety in children with epilepsy and other chronic health conditions: National estimates of prevalence and risk factors.

Authors:  Brian LaGrant; Belinda Oyinkan Marquis; Anne T Berg; Zachary M Grinspan
Journal:  Epilepsy Behav       Date:  2019-12-20       Impact factor: 2.937

7.  Value-Based Benefit Design to Improve Medication Adherence for Employees with Anxiety or Depression.

Authors:  Kimberly J Reid; Kathleen M Aguilar; Eric Thompson; Ross M Miller
Journal:  Am Health Drug Benefits       Date:  2015 Jul-Aug

Review 8.  Duloxetine: a review of its use in the treatment of major depressive disorder.

Authors:  James E Frampton; Greg L Plosker
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  Psychometric properties of an automated telephone-based PHQ-9.

Authors:  Ramesh Farzanfar; Timothy Hereen; Joseph Fava; Jillian Davis; Louis Vachon; Robert Friedman
Journal:  Telemed J E Health       Date:  2013-11-12       Impact factor: 3.536

10.  Lipopolysaccharide-Induced Behavioral Alterations Are Alleviated by Sodium Phenylbutyrate via Attenuation of Oxidative Stress and Neuroinflammatory Cascade.

Authors:  Ashok Jangra; Chandra Shaker Sriram; Mangala Lahkar
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.